Chad Pettit, MBA, executive director of Marketing and the Global Biosimilars commercial lead for Amgen, discussed the company’s 2021 Biosimilar Trends Report and his projections for the future of the biosimilars market.
In an interview with The Center forBiosimilars®, Chad Pettit, MBA, executive director of Marketing and Global Biosimilars commercial lead for Amgen, discussed the company’s upcoming 2021 Biosimilar Trends Report, which will be released in September 2021. He also talked about the outlook for the biosimilar industry.
Earlier this summer, a preview of the report was released with observations on biosimilar market share and pricing trends at the wholesale and provider levels.
Looking at the infliximab marketplace, Pettit said the slow uptake of infliximab biosimilars is not a reflection on the health of the biosimilar industry. He expects that interest in biosimilars will increase as more reference products start facing biosimilar competition and more savings are achieved.
Pettit also explained that despite fewer biosimilar approvals in 2020 and 2021, compared with earlier years, the number of biosimilar development programs the FDA is working with has increased, suggesting that a new wave of biosimilar approvals and savings can be expected in the near future.
When asked about current discounts for biosimilars, relative to the cost of reference products, Pettit said price discounts for US biosimilars average 10% to 15% and are significant. He added that cost savings will grow as more competition leads to lower prices for both reference products and biosimilars.
However, Amgen’s July 2020 launch of Avsola (infliximab) on the US market at a 57% discount from the reference product (Remicade) raises the question whether competition is sustainable. It costs money to produce biosimilars and if prices drop too far, too fast, that could discourage manufacturers.
Pettit said that competition should be on a level playing field to ensure that manufacturers are able to invest and the industry is successful.
Although the COVID-19 pandemic diverted the FDA’s attention from biosimilars in 2020, and the number of approvals declined, Pettit is optimistic that this trend will reverse, especially as more competition emerges. He also highlighted pricing trends between different types of biosimilars.
In conclusion, Pettit said the upcoming Amgen report will show that biosimilar uptake and savings data are positive and encouraging. He said that biosimilars will be instrumental in creating sustainability for the biologics market and helping to offset the massive costs often associated with disease burden.
Data Show Promise for Adalimumab Biosimilars to Deliver on Safety, Cost Savings
May 16th 2024Two posters from the Academy of Managed Care Pharmacy’s annual meeting provided hope that despite low uptake so far, adalimumab biosimilars can deliver on the promise of comparable safety and efficacy with the originator in multiple disease states, as well as cost savings.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
Challenges and Guidance in Biosimilar Assessment: An ISPOR Report on HTA Agency Approaches
May 14th 2024The ISPOR report highlights the urgent need for clear guidance on when and how to conduct health technology assessments (HTAs) for biosimilars, emphasizing the challenges faced by HTA agencies and the evolving role of HTAs in evaluating biosimilar value.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Cordavis Report Outlines Strategies for Biosimilar Development, Access in the US Health Care Market
May 8th 2024Cordavis, a CVS Healthspire company, released a report detailing the current hurdles faced in developing and commercializing biosimilars in the US and highlighting efforts by the organization to enhance access and affordability for these products.